BioSpace News Archive

Licensing agreement with Diurnal Group plc supports mission to provide individuals and families in China affected by rare diseases with the most effective medicines available in the world

Bausch Health Companies Inc. will release its fourth-quarter and full-year 2020 financial results on Wednesday, Feb. 24, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common

PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2020 financial results and operational highlights

Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

- Abbott Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales - Sales growth of 28.7 percent; organic sales growth of 28.4 percent - GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent - Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020

Catalyst Biosciences, Inc. announced the pricing of an underwritten public offering of 8,700,000 shares of its common stock, offered at a price of $5.75 per share to the public.

Thermo Fisher Scientific has developed a new medium for the development and expansion of human T lymphocytes (T-cells) for cell therapy developers using allogeneic workflows.

GeniusRx, a new digital pharmacy focused on improving patient outcomes by disrupting the way prescription drugs are bought, sold, and delivered, today announced a partnership with McKesson to automate our dispensing process.

Guardant Health, Inc. (Nasdaq: GH). Despite guideline recommendations for comprehensive genomic profiling (CGP) of all patients with advanced non-small cell lung cancer (NSCLC), profiling remains suboptimal due to continued reliance on invasive tissue biopsies for testing.